21 March 2025
HALEON PLC
("Haleon" or "the Company")
TR-1: Standard form for notification of major holdings
1. Issuer Details
ISIN
GB00BMX86B70
Issuer Name
HALEON PLC
UK or Non-UK Issuer
UK
2. Reason for Notification
An acquisition or disposal of voting rights
3. Details of person subject to the notification obligation
Name
Pfizer Inc.
City of registered office (if applicable)
New York
Country of registered office (if applicable)
United States of America
4. Details of the shareholder
| Name | City of registered office | Country of registered office |
| State Street Nominees Limited | London | United Kingdom |
5. Date on which the threshold was crossed or reached
21-Mar-2025
6. Date on which Issuer notified
21-Mar-2025
7. Total positions of person(s) subject to the notification obligation
|
| % of voting rights attached to shares (total of 8.A) | % of voting rights through financial instruments (total of 8.B 1 + 8.B 2) | Total of both in % (8.A + 8.B) | Total number of voting rights held in issuer |
| Resulting situation on the date on which threshold was crossed or reached | 0.000000 | 0.000000 | 0.000000 | 0 |
| Position of previous notification (if applicable) | 7.310000 | 0.000000 | 7.310000 | |
8. Notified details of the resulting situation on the date on which the threshold was crossed or reached
8A. Voting rights attached to shares
| Class/Type of shares ISIN code(if possible) | Number of direct voting rights (DTR5.1) | Number of indirect voting rights (DTR5.2.1) | % of direct voting rights (DTR5.1) | % of indirect voting rights (DTR5.2.1) |
| Ordinary Shares GB00BMX86B70 | | 0 | | 0.000000 |
| Sub Total 8.A | 0 | 0.000000% | ||
8B1. Financial Instruments according to (DTR5.3.1R.(1) (a))
| Type of financial instrument | Expiration date | Exercise/conversion period | Number of voting rights that may be acquired if the instrument is exercised/converted | % of voting rights |
|
| | | | |
| Sub Total 8.B1 | | | | |
8B2. Financial Instruments with similar economic effect according to (DTR5.3.1R.(1) (b))
| Type of financial instrument | Expiration date | Exercise/conversion period | Physical or cash settlement | Number of voting rights | % of voting rights |
|
| | | | | |
| Sub Total 8.B2 | | | | ||
9. Information in relation to the person subject to the notification obligation
1. Person subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuer.
| Ultimate controlling person | Name of controlled undertaking | % of voting rights if it equals or is higher than the notifiable threshold | % of voting rights through financial instruments if it equals or is higher than the notifiable threshold | Total of both if it equals or is higher than the notifiable threshold |
|
| | | | |
10. In case of proxy voting
Name of the proxy holder
The number and % of voting rights held
The date until which the voting rights will be held
11. Additional Information
This notification relates to the sale by Pfizer Inc. ("Pfizer") of the entirety of its residual interest in Haleon plc ("Haleon").
Pfizer sold 617,553,920 Haleon ordinary shares ("Ordinary Shares") pursuant to a secondary offering announced on 18 March 2025. In connection with the offering, and in addition to the 617,553,920 Ordinary Shares in the offering, Pfizer sold 44,155,844 Ordinary Shares to Haleon in an off-market sale in accordance with the terms of a share purchase deed between Haleon and Pfizer which was previously approved by Haleon's shareholders.
Pursuant to (i) the offering, and (ii) the off-market sale to Haleon, Pfizer disposed of its entire residual interest in Haleon of 661,709,764 Ordinary Shares.
Prior to the completion of (i) the offering, and (ii) the off-market sale to Haleon, Pfizer held its Haleon Ordinary Shares through State Street Nominees Limited, which held the legal title to those Ordinary Shares on Pfizer's behalf.
12. Date of Completion
21-Mar-2025
13. Place Of Completion
New York, USA
Amanda Mellor, Company Secretary
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
